---
schema_version: "secwatch.filing_event.v1"
accession: "0000805928-23-000003"
form_type: "8-K"
ticker: "AXGN"
cik: "0000805928"
company_name: "Axogen, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T18:23:57.124721+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Axogen reports preliminary Q4 2022 revenue of $36.1M, up 16% YoY ex-Avive; FY22 $138.5M, up 12%

## Summary
- Q4 revenue $36.1M, up 14% reported or 16% excluding Avive; FY22 $138.5M, up 9% reported or 12% ex-Avive.
- Cash and investments ~$55.0M at Dec 31, down from $59.4M at Sep 30; includes $5.3M capex for new Dayton, OH facility.
- 115 direct sales reps (flat YoY); 332 Core Accounts (+1% sequential); 968 Active Accounts (+2% sequential).
- Surpassed 75,000 Avance Nerve Graft implants since launch; BLA submission planned for H2 2023.
- Reaffirms FY22 gross margin above 80%; full FY23 outlook to be provided on March 14, 2023 earnings call.

## SEC filing metadata
- accession: 0000805928-23-000003
- form_type: 8-K
- ticker: AXGN
- cik: 0000805928
- company_name: Axogen, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/805928/000080592823000003/0000805928-23-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/805928/000080592823000003/axgn-20230109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000805928-23-000003
- JSON: https://secwatch.observer/filing/0000805928-23-000003.json
- Plain text: https://secwatch.observer/filing/0000805928-23-000003.txt

## Key facts
- Earnings Releases
  Axogen, Inc. reported fourth quarter and full-year 2022 results: revenue approximately $36.1 million, a 16% increase compared to fourth-quarter 2021 excluding the impact of Avive revenue in 202.
  - Period: fourth quarter and full-year 2022
  - Revenue: approximately $36.1 million, a 16% increase compared to fourth-quarter 2021 excluding the impact of Avive revenue in 202
  - Result: preliminary results
  source text: Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/805928/000080592823000003/0000805928-23-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.